Search

Geron Corp

Chiusa

SettoreSettore sanitario

0.98

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.97

Massimo

1

Metriche Chiave

By Trading Economics

Entrata

-13M

-17M

Vendite

5.6M

57M

EPS

-0.02

Margine di Profitto

-29.019

Dipendenti

258

EBITDA

-16M

-12M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+287.6% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-224M

597M

Apertura precedente

0.98

Chiusura precedente

0.98

Geron Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 nov 2026, 21:07 UTC

Macro Event

Geron Corporation shares advanced amid a broader market response to an unexpected rise in the Michigan Consumer Sentiment Index, reaching 51.0 in early November.

5 nov 2026, 21:03 UTC

Geron Corporation shares fell sharply, marking a departure from the recent trend of higher daily closes amid a broader downward movement since Wednesday.

4 nov 2026, 23:06 UTC

Geron Corporation's shares traded modestly lower in after-market hours on Wednesday, retracing from an early high and remaining below their 20-day moving average.

3 nov 2026, 22:01 UTC

Geron Corporation's shares are trading modestly lower in after-market hours, having retraced from a brief rally earlier in the session.

2 nov 2026, 21:09 UTC

Geron Corporation's shares advanced during Monday's trading session, recovering from earlier losses and reflecting a positive trend after recent declines.

30 ott 2026, 20:03 UTC

Geron Corporation shares fell sharply, continuing a three-day decline and reaching a notable low, remaining well below their 20-day moving average.

29 ott 2026, 20:07 UTC

News
Event

Wedbush maintains Outperform rating on Geron Corporation but lowers price target to $5; company discontinues Phase 3 IMpactMF trial for imetelstat.

28 ott 2026, 20:02 UTC

Social Media
Event
Macro Event
News

Geron Corporation's stock declined sharply after discontinuing its Phase 3 IMpactMF trial for imetelstat due to unlikely success in meeting primary survival endpoints.

27 ott 2026, 19:56 UTC

Geron Corporation is trading roughly flat, showing little change since Monday's close, and remains below its 20-day moving average.

26 ott 2026, 20:06 UTC

Geron Corp's shares advanced, building on previous gains.

23 ott 2026, 20:07 UTC

Geron Corp's shares are roughly flat, maintaining their position near Thursday's close amid broader market declines influenced by economic indicators and rising oil prices.

22 ott 2026, 23:46 UTC

In after-market trading, Geron Corp is advancing sharply, with a cumulative return of 3.57% since Thursday's close.

21 ott 2026, 23:41 UTC

Geron Corp shares advanced in after-market trading following Wednesday's close, briefly peaking before retracing slightly, but remain below their 20-day moving average.

20 ott 2026, 20:08 UTC

Geron Corp shares are trading higher, maintaining momentum amid a broader market trend with significant gains observed in regular trading hours.

19 ott 2026, 19:16 UTC

Geron Corp shares are advancing, reflecting broader market gains since Friday.

16 ott 2026, 23:06 UTC

Geron Corp shares advanced modestly higher in after-market trading on Friday.

15 ott 2026, 20:51 UTC

Geron Corp's shares advanced in after-market trading, rising notably from a low shortly after the close, reflecting stable performance within its one-month trading range.

14 ott 2026, 23:11 UTC

Geron Corp shares advanced in after-market trading, remaining modestly higher since Wednesday's close, despite earlier pulling back from a session high.

13 ott 2026, 20:01 UTC

Geron Corp shares are declining, remaining significantly below their 20-day moving average, with a cumulative return down since Monday's close.

12 ott 2026, 22:16 UTC

Geron Corp shares are trading lower in after-market hours, retracing from an earlier session peak and remaining below their 20-day moving average.

9 ott 2026, 19:45 UTC

Geron Corp shares are trading roughly flat, showing little change since Thursday's close and positioned below its 20-day moving average.

8 ott 2026, 23:10 UTC

Geron Corp's shares advanced in after-market trading, moving higher from a low to a high since Thursday's close.

6 ott 2026, 20:07 UTC

Geron Corp's shares fell sharply, reflecting broader market volatility, and remain significantly below their 20-day moving average amid a declining trend.

5 ott 2026, 20:06 UTC

Geron Corp's shares are advancing, recovering from earlier declines and trading higher throughout the morning, though settling near the lower end of their one-month range.

1 ott 2026, 20:07 UTC

Geron Corp shares fell sharply, continuing a downward trend and remaining below their 20-day moving average, near the lower end of their one-month range.

30 set 2026, 20:07 UTC

Geron Corp's shares are advancing, having closed higher since Tuesday, despite pulling back from an earlier session peak.

29 set 2026, 23:40 UTC

Geron Corp saw notable gains in after-market trading, reaching its highest point since Tuesday's close, though still below its 20-day moving average.

28 set 2026, 20:07 UTC

Geron Corp shares fell amid a broader market downturn, influenced by declines in major tech stocks and rising geopolitical tensions, reflecting increased volatility.

25 set 2026, 19:46 UTC

Geron Corp is trading higher, having peaked earlier before retracing, though it remains below its 20-day moving average amid broader market weakness.

24 set 2026, 20:07 UTC

Geron Corp is advancing during Thursday's trading session, having peaked in the mid-afternoon, although it remains below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Geron Corp Previsione

Obiettivo di Prezzo

By TipRanks

287.6% in crescita

Previsioni per 12 mesi

Media 3.833 USD  287.6%

Alto 5 USD

Basso 3 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Geron Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat